Q-omics provides the consensus-scored RAD51 profile across patient tissues and cancer cell-line models. RAD51 expression is associated with patient survival in 31 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RAD51 is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, RAD51 RNA expression shows 25,557 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, HNSC, and LSCC as cancer lineages where RAD51 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RAD51 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RAD51 survival associations across molecular data types. RAD51 RNA expression shows survival associations in the most cancer types (31), followed by mutation status (2) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RAD51 RNA expression–survival associations across cancer types. High RAD51 expression shows unfavorable associations in ACC, KIRP, MESO, LIHC, KICH and BRCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RAD51 RNA expression.
This table summarizes RAD51 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for RAD51. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RAD51 shows higher tumor expression in HNSC, KIRC, BLCA, LUAD, KIRP and COAD. The HNSC box plot shows higher RAD51 RNA expression in tumor versus normal tissue (log2 FC = +1.926, t-test p < 0.001).
This table shows molecular features associated with RAD51 in patient tissues and cancer cell lines. In patient samples, RAD51 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, RAD51 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BLOOD_Lymphoma.
